S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
New AI Stock Payouts (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
New AI Stock Payouts (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
New AI Stock Payouts (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
New AI Stock Payouts (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
New AI Stock Payouts (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
New AI Stock Payouts (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
New AI Stock Payouts (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
New AI Stock Payouts (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
NASDAQ:RUBY

Rubius Therapeutics (RUBY) Stock Forecast, Price & News

$0.02
0.00 (0.00%)
(As of 09/25/2023 ET)
Compare
Today's Range
$0.0032
$0.0162
50-Day Range
$0.02
$0.02
52-Week Range
$0.00
$0.50
Volume
31,816 shs
Average Volume
1.54 million shs
Market Capitalization
$1.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

RUBY stock logo

About Rubius Therapeutics (NASDAQ:RUBY) Stock

Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.

RUBY Price History

RUBY Stock News Headlines

RUBY - Rubius Therapeutics, Inc.
North American Morning Briefing: Alphabet, -2-
WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
Former Rubius CEO jumps to another Flagship spinout
Rubius Therapeutics, Inc. (RUBY)
Rubius Therapeutics Inc
Flagship-backed Vesalius lays off 43%
Rubius Therapeutics scraps platform, lays off 160
Rubius Therapeutics Announces Strategic Update
Rubius Therapeutics to Provide Strategic Update
See More Headlines
Receive RUBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rubius Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RUBY Company Calendar

Last Earnings
11/08/2021
Today
9/25/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RUBY
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

Net Income
$-179,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.17 per share

Miscellaneous

Free Float
85,687,000
Market Cap
$1.46 million
Optionable
Not Optionable
Beta
2.34
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Laurence A. Turka M.D. (Age 65)
    Chief Scientific Officer and Head of Research & Translational Medicine
    Comp: $626.55k
  • Mr. Craig R. Jalbert CIRA (Age 61)
    Pres, Treasurer, CS, Principal Exe Officer, Interim Principal Fin. & Acc. Off. and Director
  • Ms. Marissa Hanify
    Director of Corp. Communications













RUBY Stock - Frequently Asked Questions

How have RUBY shares performed in 2023?

Rubius Therapeutics' stock was trading at $0.1750 at the beginning of 2023. Since then, RUBY stock has decreased by 90.8% and is now trading at $0.0162.
View the best growth stocks for 2023 here
.

When is Rubius Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our RUBY earnings forecast
.

How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics, Inc. (NASDAQ:RUBY) announced its quarterly earnings results on Monday, November, 8th. The company reported ($0.55) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.01. During the same period in the previous year, the firm earned ($0.51) EPS.

What is Pablo Cagnoni's approval rating as Rubius Therapeutics' CEO?

12 employees have rated Rubius Therapeutics Chief Executive Officer Pablo Cagnoni on Glassdoor.com. Pablo Cagnoni has an approval rating of 91% among the company's employees. This puts Pablo Cagnoni in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Rubius Therapeutics own?
When did Rubius Therapeutics IPO?

(RUBY) raised $200 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is Rubius Therapeutics' stock symbol?

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

Who are Rubius Therapeutics' major shareholders?

Rubius Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Simplex Trading LLC (0.00%). Insiders that own company stock include Dannielle Appelhans, David R Epstein, Laurence A Turka, Maiken Keson-Brookes, Pablo J Cagnoni and Ventures Fund Iv Gene Flagship.
View institutional ownership trends
.

How do I buy shares of Rubius Therapeutics?

Shares of RUBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rubius Therapeutics' stock price today?

One share of RUBY stock can currently be purchased for approximately $0.02.

How much money does Rubius Therapeutics make?

Rubius Therapeutics (NASDAQ:RUBY) has a market capitalization of $1.46 million. The company earns $-179,670,000.00 in net income (profit) each year or ($2.38) on an earnings per share basis.

How can I contact Rubius Therapeutics?

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The official website for the company is www.rubiustx.com. The company can be reached via phone at (508) 543-1720 or via email at ir@rubiustx.com.

This page (NASDAQ:RUBY) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -